Perrigo Company plc (NYSE:PRGO) is included among the 13 Extreme Dividend Stocks with Huge Upside Potential.
On February 27, Canaccord analyst Susan Anderson lowered the firm’s price recommendation on Perrigo Company plc (NYSE:PRGO) to $17 from $20. It reiterated a Buy rating on the shares. The firm said management noted that the company finished Q4 2025 and the full year with share gains in both private label store brands and its core branded business. At the same time, the infant nutrition segment remained soft. The analyst added that the past two years have been challenging for Perrigo, largely due to issues tied to the infant nutrition business. Still, the rest of the portfolio has been performing well, supported by distribution gains, contract wins, and market share improvements in a difficult environment.
During the Q4 2025 earnings call, President, CEO, and Director Patrick Lockwood-Taylor said the company made meaningful progress throughout 2025. He said Perrigo gained traction with both consumers and retail partners. That momentum showed up in stronger market share and additional business secured with key retailers. Lockwood-Taylor explained that the company delivered earnings per share in line with its revised guidance. Operating income and EPS also improved compared with the prior year. He added that Perrigo made steady progress on its Three-S Plan, which focuses on simplifying operations, streamlining processes, and strengthening the overall business.
According to Lockwood-Taylor, market share gains accelerated as the year moved forward, reversing a multi-year trend of declines. He noted that the company captured more than $100 million in new distribution wins and competitive share gains. Lockwood-Taylor also said the store brand segment had begun to stabilize. Supply conditions in the infant formula category also improved. He added that the company announced plans to sell its Dermacosmetics business. The transaction is expected to close in the second quarter of 2026.
Perrigo Company plc (NYSE:PRGO) provides over-the-counter (OTC) health and wellness solutions designed to support individual well-being. The company operates through two segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI).
While we acknowledge the risk and potential of PRGO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRGO and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading into 2026 and 15 Best Dividend Leaders to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.
